Avience Biomedicals IPO
Avience Biomedicals IPO
Overview
Avience Biomedicals IPO is a book build issue of ₹30.24 crores. The issue is entirely a fresh issue of 0.15 crore shares of ₹30.24 crore. Avience Biomedicals IPO opens for subscription on Jun 18, 2026 and closes on Jun 22, 2026. The allotment for the Avience Biomedicals IPO is expected to be finalized on Jun 23, 2026. Avience Biomedicals IPO will list on the NSE SME with a tentative listing date fixed as Jun 25, 2026. Avience Biomedicals IPO is set issue price band at ₹196 to ₹208 per share. The lot size for an application is 600 shares. The minimum amount of investment required by an individual investor (retail) is ₹2,49,600 (1,200 shares) (based on upper price). The minimum lot size for investment in HNI is 3 lots (1,800 shares), amounting to ₹3,74,400. Fintellectual Corporate Advisors Pvt.Ltd. is the book running lead manager and Skyline Financial Services Pvt.Ltd. is the registrar of the issue. The Market Maker of the company is Asnani Stock Broker Pvt.Ltd.
Total Shares
14,53,800
Issue Size
₹30 Cr
Price Band
₹196 – ₹208
Lot Size
600 shares
Min. Investment
₹1,24,800
Max. Investment
₹1,24,800
Open Date
18 Jun, 2026
Close Date
22 Jun, 2026
Allotment
23 Jun, 2026
Listing
25 Jun, 2026
Max. Investment
₹1,24,800
Announced
18 Jun, 2026
Opening Date
18 Jun, 2026
Closing Date
22 Jun, 2026
Basis of Allotment
23 Jun, 2026
Initiation of Refunds
24 Jun, 2026
Credit of Shares
24 Jun, 2026
Listing Date
25 Jun, 2026
Live GMP
Est. Listing: ₹278
Apply via UPI in 5 minutes
Choose your broker • Zero commission on IPO
About Avience Biomedicals IPO
Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions, focusing on biotechnology, genomics, and the IVD industry.
Avience Biomedicals Limited has expanded its product range from IVD rapid test kits to a comprehensive line of medical devices, including serology products and biochemistry analyzers. This demonstrates a commitment to diverse healthcare needs, focusing exclusiv
Avience Biomedicals IPO Share Price
Issue Breakdown
Shareholding
Dilution: 36.1% increase in shares
Avience Biomedicals IPO Financial Health
Avience Biomedicals IPO Lot Size
Investors can bid for a minimum of 1,200 shares and in multiples of 600 shares thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (IND) (Min) | 2 | 1200 | ₹2,49,600 |
| Individual investors (IND) (Max) | 2 | 1200 | ₹2,49,600 |
| S-HNI (Min) | 3 | 1800 | ₹3,74,400 |
| S-HNI (Max) | 8 | 4800 | ₹9,98,400 |
| B-HNI (Min) | 9 | 5400 | ₹11,23,200 |
(All values in CR)
Avience Biomedicals IPO Valuations
| Metric | Value |
|---|---|
| ROE | 22.38 |
| ROCE | 16.99 |
| Debt/Equity | 0.94 |
| RoNW | 22.38 |
| PAT Margin | - |
| EBITDA Margin | 24.70 |
| Price to Book Value | 2.94 |
(All values in CR)
Avience Biomedicals IPO Strength & Risk
Strengths – Avience Biomedicals IPO
- Operates in the pharmaceutical and healthcare products sector with growing demand potential
- Focus on manufacturing and supplying pharmaceutical formulations and healthcare products
- Established customer relationships and distribution network
- Experienced management team with industry expertise
- Opportunity to benefit from growth in the Indian healthcare and pharmaceutical market
- Quality-focused manufacturing processes and regulatory compliance
- Scope for business expansion through increased production capacity and product portfolio diversification
- Asset creation and capacity enhancement may support future growth
Risks – Avience Biomedicals IPO
- Business is subject to stringent pharmaceutical and healthcare regulations
- Dependence on approvals, licenses, and compliance requirements
- Intense competition from established pharmaceutical and healthcare companies
- Raw material price fluctuations may impact profit margins
- Customer concentration risk if revenue depends on a limited number of clients
- Product quality issues or regulatory non-compliance could adversely affect operations
- Working capital-intensive nature of the business
- Exposure to changes in healthcare policies and industry regulations
- Risks associated with scaling operations and executing expansion plans
- Financial performance may be affected by changes in market demand and competitive pressures
Avience Biomedicals IPO GMP
Avience Biomedicals SME IPO last GMP is ₹70, last updated Jun 16th 2026 05:36 PM. With the price band of 208.00, Avience Biomedicals SME IPO's estimated listing price is ₹278 (cap price + today's GMP).The expected percentage gain/loss per share is 33.65%. >> Avience Biomedicals SME IPO Retail Subject to Sauda: ₹31900 The lowest GMP is ₹0.00, while the highest GMP is ₹70.00.
Last updated 16 Jun, 2026 · Source: aggregated grey-market dealers
| Date | IPO Price | GMP | Sub2 Sauda | Est. Listing | Est. Profit | Updated |
|---|---|---|---|---|---|---|
| 16 Jun, 2026 | 208 | ₹70 | - | ₹278 (33.65%) | 42000 | 16 Jun, 2026 |
| 15 Jun, 2026 | 208 | ₹70▲ | - | ₹278 (33.65%) | 42000 | 15 Jun, 2026 |
| 14 Jun, 2026 | 0 | ₹0 | - | ₹ (0.00%) | - | 14 Jun, 2026 |
| 13 Jun, 2026 | 0 | ₹0 | - | ₹ (%) | - | 13 Jun, 2026 |
| Invalid date | 0 | ₹0 | - | - | - | Invalid date |
Disclaimer: GMP is an unofficial signal from grey-market dealers and is not regulated by SEBI. Use it alongside subscription data and other research for informed decision-making.
How to Apply for Avience Biomedicals IPO
Login to Your Trading App
Open Zerodha, Upstox, Groww, Angel One, or any brokerage app.
Go to IPO Section
Find Avience Biomedicals IPO under the IPO section. Select it and enter your bid details — choose lot size and price (cut-off price recommended).
Enter UPI ID and Submit
Provide your UPI ID linked to your bank account and submit the application.
Approve Mandate on UPI App
Open your UPI app (Google Pay, PhonePe, Paytm, BHIM) and approve the IPO payment request.
Application Confirmed
Your funds will be blocked in your account until the IPO allotment process is completed.